New Gastroparesis Drug Naronapride Shows Clinical Promise
Adults with gastroparesis may find symptom relief with this dual-action drug, which showed positive results in a 12-week trial.
Updated on Oct. 30, 2026 in Diabetes
Live Poll
Is pharmaceutical research for chronic digestive conditions significantly improving quality of life for patients?
A phase 2b trial presented in October 2026 shows that the drug naronapride may improve symptoms for adults with diabetic or idiopathic gastroparesis. The 12-week study evaluated whether the dual-action prokinetic could offer relief for those struggling with the digestive condition.
Why it matters
Managing gastroparesis is challenging, and this preliminary trial suggests a new treatment path that targets gut motility without disrupting glycemic control. These results highlight a potential option for patients, though further research is required to confirm safety and long-term efficacy.
This phase 2b randomized trial of 328 adults with idiopathic or diabetic gastroparesis evaluated naronapride over a 12-week period. While 20 mg and 40 mg doses demonstrated significant improvements in core symptoms and quality of life versus placebo, the findings remain preliminary.
The players
Naronapride
An investigational dual-action prokinetic drug designed to address gastroparesis symptoms.
The details
Naronapride functions as a dual-action prokinetic agent that aims to restore normal stomach function. It works by stimulating serotonin receptors to increase gastrointestinal motility while simultaneously blocking dopamine receptors to help mitigate nausea. The study utilized a 0-4 scale to measure changes in weekly symptom scores among participants, who had a mean age of 51.1 years.
Timeline
The clinical trial treatment lasted for 12 weeks.
Study results were presented in October 2026 at United European Gastroenterology Week.
Health Landscape
Gastroparesis treatment currently relies on a narrow field of motility-enhancing agents with varying success. This trial positions naronapride as a potential new approach that modulates both serotonin and dopamine receptors to address symptoms.
While these findings are encouraging, it is important to note that the study reported higher discontinuation rates due to side effects like diarrhea in the treatment group. If you are managing gastroparesis, discuss these preliminary results with your gastroenterologist to see how current research aligns with your ongoing care plan.
The takeaway
Naronapride shows promise in managing gastroparesis symptoms by targeting gut motility through multiple pathways. Patients should monitor symptom patterns closely and maintain a detailed log to share with their care team during routine checkups.
Further reading
For more on managing long-term health, explore our Diabetes section.
Source note: This article includes information reported by Medscape.
Live Poll
Is pharmaceutical research for chronic digestive conditions significantly improving quality of life for patients?
